@inbook{cdde9ec53f464c65a2c958e873cbd1e1,
title = "Next generation antidepressants with novel mechanisms for treatment resistant depression",
abstract = "Evidence has suggested that the modulation of N-methyl-D-aspartate receptors (NMDARs) and 5-hydroxytryptamine receptors (5-HTRs) via the psychedelic drugs, such as ketamine and psilocybin, rapidly alters the state of consciousness and the neuroplasticity. The United State Food and Drug Administration approved the indications of esketamine for treatment-resistant depression (TRD) in 2019 and major depressive disorder with suicidal ideation in 2020. The phase 2 clinical trials also discovered the rapid and sustained antidepressant effects of psilocybin among patients with TRD. In this chapter, we discussed the complex among the consciousness, neuroplasticity, and novel rapid-acting antidepressants and their possible neuromechanisms.",
keywords = "Consciousness, Depression, Ketamine, Neuroplasticity, Novel antidepressants, Psilocybin, Psychedelics",
author = "Chen, {Mu Hong} and Tu, {Pei Chi} and Su, {Tung Ping}",
note = "Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",
year = "2023",
month = jan,
doi = "10.1016/bs.pbr.2023.02.005",
language = "English",
isbn = "9780323957786",
series = "Progress in Brain Research",
publisher = "Elsevier B.V.",
pages = "149--168",
editor = "Cheng-Ta Li and Chih-Ming Cheng",
booktitle = "Treatment-Resistant Depression Part A",
address = "荷蘭",
}
